Researchers at Stanford University have discovered a way to enhance the effectiveness of CAR-T cell therapeutics through inducing a more memory-like phenotype.
Researchers at Stanford have created a method to differentiate human pluripotent stem cells (hPSCs) into >90% pure hematopoietic stem cell (HSC)-like cells, which serve as progenitors to blood and immune cells.
Stanford researchers at the Zhao Lab have designed milli-spinner thrombectomy devices that mechanically debulk clots by safely shredding the clots for fast and complete clot removal.
Stanford researchers in the Zhao Lab have developed a mechanical thrombectomy device for Pulmonary Embolism (PE) that mechanically debulks and reduces volume of large clots without causing fragmentation.
A new deep-learning system called Atomic Rotationally Equivariant Scorer (ARES) significantly improves the prediction of RNA structures over previous artificial intelligence (AI) models.
The cost of DNA and RNA sequencing have decreased in recent years to aid effective research and clinical applications; however, the labor time and throughput of preparing DNA and RNA sequencing libraries remains a challenge.
Stanford researchers have found that a chemokine receptor antagonist can reduce immunosuppression in the tumor microenvironment and thereby delay tumor progression.
Stanford researchers have developed easyBAT, a simplified solution integrating a microfluidic sample preparation device with a fully automated analysis pipeline for rapid, accurate and accessible solution for food allergy diagnosis at the point-of-care.
Stanford researchers have developed a new technology, Variant-FlowFISH, to enable high-throughput, highly sensitive measurements of how variants, introduced via CRISPR, affect gene expression.
Stanford scientists have developed a novel hydrogel for long-term drug delivery of an Activator Protein 1 (AP-1) inhibitor for the prevention of post-surgical abdominal adhesion.
Stanford researchers have developed a high-affinity IL-11 decoy cytokine for super-agonism and antagonism of the IL-11 receptor, enabling the treatment of a wide variety of diseases from inflammatory disease to cancer as well as research into IL-11 signaling pathways.
Stanford researchers have developed a pioneering gene therapy by targeting reactive astrocytes in the optic nerve head (ONH) and modulating cyclic adenosine monophosphate (cAMP) levels for targeted treatment of glaucoma and other retinal disorders.